Loading…
Alnylam Pharmaceuticals, Inc. is projected to rise to $379.66 by 2027, a +32% move from its current price of $288.41. ALNY is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/29/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 31 | $282.75 | $288.64 | $294.66 | +0.08% |
| Aug 1 | $280.57 | $288.88 | $297.43 | +0.16% |
| Aug 2 | $278.97 | $289.12 | $299.63 | +0.24% |
| Aug 3 | $277.66 | $289.35 | $301.54 | +0.33% |
| Aug 4 | $276.53 | $289.59 | $303.26 | +0.41% |
| Aug 5 | $275.54 | $289.82 | $304.84 | +0.49% |
| Aug 6 | $274.65 | $290.06 | $306.33 | +0.57% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $274.65 | $290.06 | $306.33 | +0.57% |
| Week 2 | $270.05 | $291.72 | $315.12 | +1.15% |
| Week 3 | $266.92 | $293.39 | $322.47 | +1.73% |
| Week 4 | $264.55 | $295.06 | $329.09 | +2.31% |
| Week 5 | $262.66 | $296.75 | $335.27 | +2.89% |
| Week 6 | $261.10 | $298.45 | $341.13 | +3.48% |
| Week 7 | $259.80 | $300.15 | $346.78 | +4.07% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Alnylam was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY trades at $288.41 with a market cap of $38.51B, ranking 369.
The stock sits in a near-term technical picture that shows bearish sentiment, with RSI(14) at 40 and moving averages near key levels: SMA50 at $292.02 and SMA200 at $354.46. The 30-day range runs from $251.74 to $330.42, with a defined support at $266.99 and resistance at $323.50. Annualized volatility is around 40%.
Looking ahead, the year-by-year forecast points to rising averages from 2026 through 2050, with 2026 avg at $288.41, 2027 avg at $379.66, 2030 avg at $470.17, 2040 avg at $1,048.97, and 2050 avg at $1,888.41; the implied ROIs progress from 0% in 2026 to 31.6% (2027), 43.7% (2028), 53.4% (2029), 63% (2030), 71.3% (2031), 89.8% (2032), 129.8% (2033), 145.7% (2034), 151.6% (2035), 263.7% (2040), and 554.8% (2050).
A major floor 19.2% below — a decisive break under it would weaken the trend.
The nearest floor, 7.4% below — buyers have tended to step in here.
The nearest ceiling, 12.2% above — a clean break opens room to run.
A major ceiling 20.0% above — clearing it would confirm fresh momentum.
Key ALNY support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALNY market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $271.63 | Buy | $273.82 | Buy |
| MA 10 | $275.73 | Buy | $278.18 | Buy |
| MA 20 | $291.37 | Sell | $284.66 | Buy |
| MA 50 | $292.02 | Sell | $293.11 | Sell |
| MA 100 | $303.39 | Sell | $307.89 | Sell |
| MA 200 | $354.46 | Sell | $326.53 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.23 | Neutral |
| Stoch RSI (14) | 28.62 | Neutral |
| CCI (20) | -55.26 | Neutral |
| Williams %R (14) | -79.81 | Info |
| MACD (12,26,9) | -2.58 | Sell |
| ROC (12) | -13.94 | Sell |
| Bollinger %B (20,2) | 0.32 | Neutral |
| Stochastic %K (14) | 20.19 | Neutral |
| TRIX (15) | -0.18 | Sell |
| Awesome (5,34) | -18.84 | Sell |
| Ultimate (7,14,28) | 44.18 | Neutral |
| Momentum (10) | -20.36 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 268.96 | Buy |
| ADX (14) | 19.29 | Neutral |
| ATR (14) | 5.84 | Info |
The 30-day picture is bearish, with RSI(14) at 40 reflecting cautious momentum.
SMA50 sits at $292.02 and SMA200 at $354.46, placing the near-term trend below the short- and medium-term moving averages.
The 30-day range spans $251.74 to $330.42, with a support level at $266.99 and a resistance at $323.50. The stock exhibits about 40% annualized volatility, underscoring a choppy short-term environment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $266.99 | $288.41 | $410.45 | 0% | Neutral | |
| $309.45 | $379.66 | $488.06 | +32% | Bullish | |
| $330.95 | $414.55 | $548.78 | +44% | Bullish | |
| $347.17 | $442.34 | $599.20 | +53% | Bullish | |
| $363.55 | $470.17 | $649.39 | +63% | Bullish | |
| $376.90 | $494.06 | $694.10 | +71% | Bullish | |
| $412.53 | $547.56 | $781.11 | +90% | Bullish | |
| $493.44 | $662.64 | $958.51 | +130% | Bullish | |
| $521.90 | $708.63 | $1,038.27 | +146% | Bullish | |
| $528.84 | $725.64 | $1,075.94 | +152% | Bullish | |
| $729.34 | $1,048.97 | $1,635.67 | +264% | Bullish | |
| $1,213.66 | $1,888.41 | $3,171.73 | +555% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $266.99 | $288.41 | $337.27 | +0.00% |
| August 2026 | $254.43 | $297.23 | $354.28 | +3.06% |
| September 2026 | $264.30 | $310.65 | $373.99 | +4.52% |
| October 2026 | $267.07 | $315.47 | $382.84 | +1.55% |
| November 2026 | $270.07 | $320.32 | $391.25 | +1.54% |
| December 2026 | $280.61 | $334.07 | $410.45 | +4.29% |
Click any year to see its month-by-month ALNY forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ALNY to range from $266.99 to $410.45 through 2026. The $288.41 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ALNY price prediction for 2027 points to an average of $379.66 (low $309.45, high $488.06) — a potential gain of +32% on today's $288.41. Momentum favours further upside here.
In 2028, ALNY is projected to trade between $330.95 and $548.78, averaging $414.55 — a potential gain of +44% from today's $288.41. That is up +9% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Alnylam Pharmaceuticals, Inc.'s 2029 outlook centres on $442.34, within a $347.17 to $599.20 range. That is up +7% on the projected 2028 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2030, ALNY could reach as high as $649.39, with a base case around $470.17 and support toward $363.55 — roughly +63% from $288.41. Buyers look set to stay in control over this stretch.
Expect ALNY to range from $376.90 to $694.10 through 2031. The $494.06 average target implies a +71% move from current prices. That is up +5% on the projected 2030 average. Momentum favours further upside here.
The ALNY price prediction for 2032 points to an average of $547.56 (low $412.53, high $781.11) — a potential gain of +90% on today's $288.41. Buyers look set to stay in control over this stretch.
In 2033, ALNY is projected to trade between $493.44 and $958.51, averaging $662.64 — a potential gain of +130% from today's $288.41. That is up +21% on the projected 2032 average. Momentum favours further upside here.
Alnylam Pharmaceuticals, Inc.'s 2034 outlook centres on $708.63, within a $521.90 to $1,038.27 range. That is up +7% on the projected 2033 average. That marks a +146% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ALNY could reach as high as $1,075.94, with a base case around $725.64 and support toward $528.84 — roughly +152% from $288.41. Momentum favours further upside here.
Expect ALNY to range from $729.34 to $1,635.67 through 2040. The $1,048.97 average target implies a +264% move from current prices. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ALNY price prediction for 2050 points to an average of $1,888.41 (low $1,213.66, high $3,171.73) — a potential gain of +555% on today's $288.41. Momentum favours further upside here.
Investing $1,000 in ALNY today (≈ 3.467286 ALNY) could be worth
$6,547.67
+$5,547.67 (+555%) by 2050 · US Dollar
Based on the average projected ALNY price of $1,888.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALNYwould be worth at today's price.
$1,000 invested in ALNY on Jul 28, 2025 (≈ 3.078912 ALNY) would be worth
$887.99
-$112.01 (-11.2%) today · 0.89× · US Dollar
Based on a ALNY entry price of $324.79 vs. today's $288.41.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $272.67 | $1,057.73 | +5.8% |
| 1 month ago | $291.37 | $989.84 | -1.0% |
| 3 months ago | $302.11 | $954.65 | -4.5% |
| 6 months ago | $349.58 | $825.02 | -17.5% |
| 1 year ago | $324.79 | $887.99 | -11.2% |
| All time (5.0y) ago | $177.96 | $1,620.65 | +62.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALNY forecast.
Our base-case forecast reaches $580.00 around 2033.
Implied market cap at $580.00: $77.44B
The multi-year forecast implies a bullish trajectory beyond 2026, with the average price climbing from $288.41 in 2026 to $379.66 in 2027 and continuing higher through 2050, where the average is $1,888.41.
Key milestones include 2030 avg $470.17 (ROI 63%), 2040 avg $1,048.97 (ROI 263.7%), and 2050 avg $1,888.41 (ROI 554.8%), with higher year-by-year figures intermediate along the path. These projections reflect a sustained upside potential but are not guarantees; actual results depend on factors not guaranteed by the numbers.
Overall, the outlook signals meaningful upside evidence across the long horizon, with increasing average prices and substantial ROIs in the later years, tempered by near-term caution given the current bearish sentiment and volatility.
Tap a question to reveal the answer.
Avg $288.41; min $266.99; max $410.45; ROI 0%; sentiment NEUTRAL.
The forecast shows a path of rising averages from 2026 onward, with 2027 avg $379.66 and 2030 avg $470.17, culminating in a 2050 avg of $1,888.41 and ROI up to 554.8%. These are estimates and not guarantees.
Yes, the forecast includes 2034 max $1,038.27 and 2035 max $1,075.94, with 2040 max $1,635.67, indicating the potential to exceed $1,000 in the forecast horizon.
Current price is $288.41 and market cap is $38.51B.
Avg $1,048.97; min $729.34; max $1,635.67; ROI 263.7%.
Alnylam Pharmaceuticals, Inc. Community Discussion
0Share your Alnylam Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.